瑞科生物-B：2023年報

Futu NewsApr 16 21:59 · Announcements

Recco Bio-B (02179) nominated Liu Yong as a candidate for the second board of directors

The term of directors of the second board of directors is three years. It takes effect from the date the relevant bill is reviewed and passed by the company's shareholders' meeting. At the end of their term of office, they can be re-elected.

Zhitong FinanceApr 15 19:32

Recobiotics and Rongsheng Biotech sign a strategic cooperation agreement on a novel adjuvant vaccine project

Taizhou, March 27, 2024/PRNewswire/ -- Recently, Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiology”, stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biotech”) successfully held a novel adjuvant vaccine R&D project signing and project launch meeting in Shanghai. At the meeting, the two sides signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed in depth the details of the project progress. Adjuvants are important components in vaccine development, and novel adjuvants have become the key to the success of innovative vaccine development. According to this section of the agreement

PR NewswireMar 27 11:01

Jiangsu Recbio Technology's Loss Narrows in 2023

Jiangsu Recbio Technology's (HKG:2179) attributable loss narrowed to 572 million yuan, or 1.19 yuan per share, in 2023, from 722.7 million yuan, or 1.52 yuan per share, in 2022, according to a Wednesd

MT NewswiresMar 21 18:32

Recobiotics Releases 2023 Annual Results Report and Recent Developments

Taizhou, Jiangsu Province, March 21, 2024/PRNewswire/ -- On March 20, innovative vaccine company Recobiology (02179.HK) released its 2023 annual results report and latest developments. Recobiology has always adhered to the vision and mission of “creating first-class vaccines to protect human health”, guided by the company's strategy, and has achieved the following milestones and progress in research and pipeline and business operations. Business Summary REC603-recombinant HPV nine-valent vaccine The recombinant nine-valent HPV vaccine REC603 is undergoing phase III clinical trials in China, and regular follow-up work is being carried out according to the clinical plan.

PR NewswireMar 21 00:18

Recco Bio-B (02179) announced annual results, loss attributable to shareholders of 572 million yuan narrowed 20.86% year over year

Recco Bio-B (02179) announced its annual results for the year ended December 31, 2023. The group...

Zhitong FinanceMar 20 18:28